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Molecular engineering of vein bypass grafts
Michael S. Conte, MD, Boston, Mass
Surgical bypass of arterial occlusions using autogenous vein provides an effective treatment for many patients with
advanced coronary or peripheral atherosclerosis. However, the long-term benefit of bypass surgery is limited by the
development of de novo occlusive lesions within the vein graft, which occurs in a significant percentage of patients over
time. The pathophysiology of vein graft failure involves a complex interplay between an acute vascular injury response and
the hemodynamic adaptation of the vein to arterial forces. Cell proliferation, inflammation, and matrix metabolism are
critical components of postimplantation remodeling. Conventional pharmacotherapy has had limited impact on graft
failure. Vein grafts present a unique and attractive opportunity for molecular engineering, which is defined for purposes
of this review as the local application of genomic (eg, gene transfer or gene inhibition) or proteomic interventions
designed to alter the healing response. The critical enabling technologies for these strategies are described, with a
perspective on preclinical and clinical development for this indication. The recently completed clinical trials of edifoligide
(E2F decoy oligodeoxynucleotide) provide important lessons for future studies. A better understanding of the remod-
eling response of vein grafts in humans is required to design effective molecular therapies and to define the appropriate
target populations and surrogate markers for future clinical trials. ( J Vasc Surg 2007;45:74A-81A.)Despite an increasing application of endovascular tech-
niques, surgical bypass grafting remains a mainstay of ther-
apy for many patients with advanced coronary and periph-
eral atherosclerosis. Autogenous vein has proven to be an
effective and versatile arterial substitute. In the lower ex-
tremity, however, vein graft stenosis or occlusion occurs in
30% to 50% of cases5 years, and50% of coronary grafts
fail10 years, leading to significant morbidity and mortal-
ity. For many patients with advanced peripheral arterial
disease (PAD), failure of a bypass graft may lead directly to
major limb amputation and diminished quality of life.
Limited available autogenous conduit, the lack of a suitable
small caliber arterial prosthetic, and the frequency of coex-
istent coronary and peripheral disease combine to elevate
the importance of maintaining patency for each individual
vein graft.1,2
To date, conventional pharmacology has produced
limited benefits for vein graft patients. Recognition of the
significant unmet clinical need in this area has spurred
interest in developing novel molecular approaches, includ-
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74Aing genetic modification strategies, to prevent bypass graft
failure. Some of these therapeutic agents have reached the
stage of advanced clinical trials.
Advances in genomics, proteomics, and drug delivery
technology offer an increasing array of tools for modulating
cellular function in vivo. Vein grafts present an attractive
target for local molecular therapy because the target tissue
is directly accessible and may be treated ex vivo (or in situ)
at the time of implantation. Furthermore, because the
surgical procedure effectively denotes the initiation of the
pathophysiologic events within the vein, there is potential
to re-engineer the cellular programs that mediate the heal-
ing response at “time zero.” With that concept as an
underlying premise, this review will outline some of the
approaches that have been under investigation and the
current status of translational research in this area.
VEIN GRAFT FAILURE: PATHOPHYSIOLOGIC
CONSIDERATIONS
In the lower extremity, where vein graft surveillance is
simplified because of anatomic position, three distinct
phases of graft failure are recognized.3 Early graft occlusion
(ie, 30 days), which occurs in 5% to 10% of cases, is
generally ascribed to technical complications but also in-
cludes problems intrinsic to the conduit (eg, small diameter
or pre-existing vein pathology) as well as extrinsic causes
(eg, limited outflow, hypercoagulability). Mid-term (3 to
24 month) and late (2 years) vein graft failures are most
commonly ascribed to the development of fibrotic intimal
hyperplasia (IH) and atherosclerotic degeneration, respec-
tively. Rates of reintervention for lower extremity grafts are
highest in themid-term period, focusing attention on IH as
a critical process for therapeutic targeting.
The cell and molecular biology of IH have been best
characterized in the context of acute arterial injury such as
e inhi
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been suggested by experimental models of vein grafting in
animals, particularly with regard to smooth muscle cell
(SMC) activation, migration, and proliferation. Currently
available animal models, including vein graft techniques in
murine, rabbit, pig, and nonhuman primate species, have
varying strengths and weaknesses for basic and preclinical
investigations.4 For the most part, these models provide
insight into the arterialization response of veins but have
limited utility for the study of graft failure. The adaptation
of vein grafts to the arterial environment has been studied
to a far lesser extent in humans.
After implantation, vein grafts universally undergo
structural changes characterized by the formation of a
proliferative neointima and overall wall thickening, result-
ing in a reduction in wall tension. The view of vein graft
stenosis as an exaggerated form of this adaptation process
remains to be proven and, by analogy to postangioplasty
arterial remodeling, may be an oversimplification. A broad
review of the pathophysiology of vein graft disease is be-
yond the scope of this article, and the reader is referred to
several excellent reports on this subject.5-7 The Table sum-
marizes the major cellular processes that may be considered
for therapeutic intervention. This list is by no means meant
to be exhaustive, but rather provides an overview of the
relevant spectrum, with appropriate examples of molecular
targets for potential vein graft therapies.
Among the cellular processes outlined in the Table,
SMC growth has received the greatest attention as the most
critical determinant of vein graft IH. Although recent
observations suggest that this focus may be inappropriately
myopic, most would agree that an excessive SMC prolifer-
ative response within the vein is deleterious. Fueled by an
increased understanding of the fundamental processes of
cell growth (cell cycle machinery) and death (apoptosis and
its regulation), investigators have explored an array of tar-
geted molecular interventions to control SMC growth in
vascular injury settings.
A variety of cell cycle inhibitors and proapoptotic strat-
Table. Major pathophysiologic processes relevant to vein
window of treatment for which a local intervention would
1st process 2nd processes
EC function EC regeneration VE
EC dysfunction N
SMC growth SMC proliferation Ce
SMC apoptosis IA
Cell migration TI
Inflammation I/R, oxidative stress Cy
Leukocyte recruitment Ad
Thrombosis Platelet activation Pr
Thrombin activation Th
Matrix/fibrosis M
EC, Endothelial cell; SMC, smooth muscle cell; VEGF, vascular endothelia
superoxide dismutase(s); IAP, inhibitor of apoptosis protein; TIMP, tissu
reperfusion; ADPases, adenosine diphosphohydrolase(s).egies have been studied in vein graft models. The transcrip-tion factor E2F, a critical regulator of cell cycle progression
that coordinates the activation of several genes, was consid-
ered an attractive therapeutic target (see edifoligide trials
below).
As another example, our recent work has focused on
the intersection of cell survival and proliferation pathways.
The inhibitor of apoptosis protein (IAP) survivin is unique
in having dual critical functions regulating mitosis and
preventing apoptosis under conditions of cellular stress.
These functions have stimulated intense interest in survivin
as a potential target for cancer therapy, and we have re-
cently demonstrated the relevance of survivin to vascular
injury and vein grafting in particular.8-12 Local knockdown
Fig 1. Regulation of intimal hyperplasia in rabbit vein grafts by
local modulation of the inhibitor of apoptosis protein (IAP) sur-
vivin. Rabbit jugular vein carotid interposition grafts were treated
at implantation with adenoviral vectors encoding a dominant-
negative form of survivin (AdT34), wild-type survivin (AdWT), or
an irrelevant gene (AdGFP). Panel A, Representative histology
(I, Intima;M,media, A, adventitia) at 4 weeks. Panel B,morpho-
logic analysis at 4 weeks. A significant (41%) reduction in wall
thickness was observed in AdT34 treated grafts, and a correspond-
ing increase (37%) was observed in AdWT treated grafts that
overexpressed survivin.10
disease, examples of molecular targets, and temporal
kely to have a beneficial effect
Molecular targets Temporal Rx window
Time 0—weeks
O-1, SOD Time 0—months
le genes, growth factors 2-3 days—weeks
roapoptotics 2-3 days—weeks
PAs Time 0—weeks
tectants (NOS, SOD, HO-1) Time 0—weeks
n molecules, chemokines Time 0—weeks
yclin, ADPases, Time 0—long term
in inhibitors, PAs Time 0—long term
genes Weeks—months
th factor; NOS, nitrix oxide synthase(s); HO-1, heme oxygenase-1; SOD,












l growof survivin using a dominant negative gene, delivered by
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ically altered the healing response of rabbit vein grafts.
SMC proliferation was reduced and apoptosis correspond-
ingly increased at 1 week; at 4 weeks, IH was significantly
attenuated (Fig 1).10 Further studies are needed to deter-
mine if such combined antiproliferative/proapoptotic
strategies may have useful application to surgical bypass
grafting.
In a review of the Table and the growing literature on
which it is based, several key features emerge that will
ultimately determine the clinical success of interventions
designed to improve vein graft patency. First, there is great
redundancy in the molecular pathways that contribute to
IH, similar in many ways to the problems of wound healing
and fibrosis in general. Thus, strategies limited to a single
gene or pathway are inherently risky unless that target has
overlapping influence across several processes or is uniquely
potent in determining the overall response. In addition,
each pathway has a unique temporal window for interven-
tion, though considerable overlap exists. The pharmacoki-
netics of the molecular intervention must match the tem-
poral course of the process being targeted within the vein.
Our knowledge of these events is limited almost exclu-
sively to animal studies of vein graft adaptation and is
greatly hampered by an incomplete understanding of the
process in humans (see subsequent section). However, this
daunting complexity is tempered by the realization that
clinical outcome may be significantly improved by even a
moderate shift in one or more of the biologic processes that
participate in graft healing. The observation that many vein
grafts function well beyond 10 years attests to the fact that
an autogenous vein has the potential to serve as an excellent
long-term arterial replacement. A re-engineering of the
healing response to moderate, rather than obliterate, cell
growth (for example) may potentially yield a meaningful
increase in long-term graft survival.
LOCAL DELIVERY OF BIOMOLECULES:
CRITICAL TECHNOLOGIES
For the purpose of this review, we will focus on the use
of locally delivered biomolecules—defined as genes, oligo-
nucleotides, proteins, and peptides—for therapeutic ma-
nipulation of the vein graft injury response. These may be
broadly characterized into “genomic” (strategies designed
to influence gene expression) or “proteomic” (strategies
designed to influence protein function) approaches and are
distinguished from conventional pharmaceuticals both by
the nature of the agent and by the local delivery of these
agents to the target tissue (vein) of interest.
Genomic strategies
Genomic strategies may take several forms.
Gene replacement or augmentation. These ap-
proaches involve the delivery of an intact gene that is either
missing, present in a defective form or simply under-
expressed relative to the level of protein product desired.
Genes encoding proteins that are secreted or that generate
diffusible mediators are attractive because delivery to asubpopulation of cells may yield a therapeutic result. Ex-
amples of this category of genes with vascular applications
include the nitric oxide synthase (NOS) isoforms, which
yield a readily diffusible product, nitric oxide (NO), throm-
bin inhibitors, or plasminogen activators. Other genes of
interest may act exclusively in an intracellular fashion, alter-
ing the phenotype of the transfected cell for potential
therapeutic purposes. Achieving gene transfer to most of
the cells within a vein graft is a significant hurdle, however,
particularly within the temporal constraints of an intraop-
erative protocol.
Genes are large, double-stranded DNA molecules that
are inefficiently taken up by cells, and therefore, a special-
ized delivery system (“vector”) is required. Gene delivery
vectors may be divided into two categories: viral and non-
viral. For a more complete review of gene transfer vectors,
the reader is referred to a number of excellent treatments of
this topic.13-16
Current available gene transfer vectors vary substan-
tially in critical clinical attributes such as efficiency, stability
of transgene expression, and host response. The ideal vec-
tor for a vein graft therapy depends on the nature of the
gene being delivered as well as the temporal and spatial
requirements of the molecular program being targeted. For
example, endothelial cell (EC) targeting to promote graft
thromboresistance (eg, by overexpression of a thrombin
inhibitor) would have different requirements compared
with suppressing proliferation within medial SMCs. Mini-
mization of local or systemic inflammatory reactions to the
vector is obviously also critical.
At the present time, adenoviral vectors are most com-
monly used in experimental cardiovascular studies and pro-
vide a useful compromise.17,18 Adenoviruses infect vascular
cells readily and can yield high levels of transgene expres-
sion for a short time period (1 to 2 weeks in vivo). How-
ever, a dose-dependent inflammatory response to the
widely available first-generation and second-generation ad-
enoviral vectors is well described and has been shown to
exacerbate intimal hyperplasia in some models of vascular
injury.19 Other viral vectors, including adeno-associated20,21
and lentiviral systems,22,23 offer unique potential advan-
tages, but to date, have been limited primarily by low
efficiency in vascular models.
For intraoperative vein graft therapy, safety and effi-
ciency are paramount, and each unique gene-vector com-
bination being considered will require careful characteriza-
tion and optimization in appropriate preclinical models.
These delivery obstacles have dampened enthusiasm for the
clinical development of gene-based approaches, but the
therapeutic potential of this strategy remains enormous.
Gene inhibition. Another broad category of genetic
manipulation is gene inhibition. A specific gene, or an
entire cellular program (eg, cell cycle), may be inhibited
using small nucleic acid molecules called oligonucleotides.
These may function to block the translation of specific
messenger RNAs, for example, antisense oligonucelotides,
ribozymes, or small interfering RNAs (si)RNAs. They can
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factors) that control gene expression.
Antisense oligodeoxynucleotides (AS-ODN) are de-
signed to have a base sequence that is complementary to a
segment of the target gene.24,25 They are generally 15 to
20 bases in length, which confers specificity to the target
messenger RNA (mRNA). This binding of ODN tomRNA
either results in enzymatic degradation of the mRNA or
prevents the translation of RNA into its protein product. A
related form of gene blockade involves the use of ri-
bozymes, segments of RNA that can act like enzymes to
destroy specific sequences of target mRNA.26
Yet another type of gene inhibition involves the antag-
onism of transcription factors. Transcription factors regu-
late gene expression by binding to chromosomal DNA at
specific promoter regions, and this binding turns on, or
activates, an adjacent gene. Transcription factor decoys are
double-stranded ODN designed to mimic the genomic
binding sites of the target transcription factors. Once deliv-
ered to a cell, the decoy ODN binds to the available
transcription factor, competitively inhibiting the transcrip-
tion factor–promoter interaction and thereby preventing
the subsequent activation of target genes.27
Recently, a powerful new approach to inhibit specific
gene expression has been elucidated based on the intracel-
lular effects of double-stranded (ds) RNA molecules.28
This phenomenon, termed RNA interference is mediated
by short (21 to 23 nucleotide) dsRNA constructs known as
siRNAs. Intracellular processing of siRNAs culminates in
their incorporation into a multiprotein complex, called the
RNA-induced silencing complex (RISC), which may then
recognize and cleave specific mRNA molecules that have
homology to the siRNA. This mechanism yields effective
and specific silencing of the targeted gene, usually in a
transient fashion.
Delivery of siRNAs to cells and tissues may be accom-
plished in a variety of ways, with interest increasing in the
use of lentiviral vectors to achieve longer-term suppression
of target genes by sustained intracellular production of the
siRNA molecules. To date there have been limited studies
examining the application of siRNA to blood vessels in
vivo, and further investigation is needed to determine the
clinical applicability of this approach.
In general, a major attraction of these gene inhibition
strategies is that small synthetic ODN (typically 1/1000
the size of an entire gene) may be delivered more easily to
cells and tissues with high efficiency and often do not
require specific vectors. For example, the use of nondis-
tending pressure has been shown to result in the rapid
uptake of ODN by80% of cells within the saphenous vein
wall during a 10-minute exposure.29 Delivery efficiency
and stability of target gene knockdown will be different for
single-stranded AS-ODN vs double-stranded decoy-ODN,
however, and siRNA molecules constitute an entirely dis-
tinct class in their pharmacologic attributes. Further studies
are needed to determine if the exciting potential of these
small molecule genetic approaches can be realized for com-plex in vivo applications such as vein bypass grafting or
postangioplasty restenosis.
Proteomic strategies
Proteomic strategies seek to directly modify the profile
of functional protein species (proteome) within the target
tissue to achieve a desirable effect. Examples would include
the directed delivery of biologically active proteins or pep-
tides, or the modification of post-translational processing
(eg, glycosylation) steps that are critical for protein func-
tion. Although pharmacologic obstacles for systemic (eg,
oral or parenteral) delivery of proteins and peptides are well
known and substantial, the development of critical platform
technologies for local delivery of these agents has acceler-
ated. In particular, the discovery of cell permeability do-
mains, also called peptide/protein transduction domains
(PTDs), from the human immunodeficiency virus (HIV-1)
TAT protein30,31 and other sources (eg, antennapedia ho-
meodomain protein,32 VP22 protein from herpes simplex
virus)33 has allowed for the creation of fusion constructs
capable of efficiently delivering peptides and small proteins
directly into cells.34 In parallel, the development of high
throughput techniques (eg, antibody-based microarrays,
mass spectrometry) to profile proteins and peptides from
normal and diseased tissues offers the potential to charac-
terize complex diseases at the proteomic level. This field is
in its infancy but can be expected to yield new insights and
therapeutic opportunities for cardiovascular disorders in-
cluding IH and vein graft disease.
Local delivery platform technologies
Local delivery platform technologies have revolution-
ized the field of drug delivery during the last decade. The
development of novel polymers and matrices for the mod-
ification of biomaterials (eg, intravascular stents) has been
dramatic and offers the potential for programmable deliv-
ery of a variety of molecules directly to target tissues such as
native vessels and vascular grafts. This technology has rele-
vance for both genomic and proteomic approaches tomod-
ify vascular responses, as well as creating new opportunities
for conventional drugs (eg, rapamycin) that may have fa-
vorable local effects if their systemic toxicity can be mini-
mized.
There are broad implications of these local delivery
platforms for cardiovascular surgery. For example, the he-
mostatic or tissue adhesive properties of a polymer carrier
may be leveraged for simultaneous delivery of a drug or
biomolecule to the site of a surgical anastomosis. For vein
graft applications, molecular therapy may take a variety of
forms, such as a preimplantation “soak” of a cell-permeable
peptide construct, or periadventitial application of a poly-
mer depot containing a protein, peptide, or genetic agent.
The increased recognition of the role of the adventitia in
modulating vein graft IH as led several investigators to use
periadventitial gene delivery in animal models, with prom-
ising results. Several biotechnology companies are explor-
ing approaches to modulate the hyperplastic response at
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BENCH TO BEDSIDE: THE EDIFOLIGIDE
STORY
The principles described above were used to develop an
ODN-decoy approach targeting SMC proliferation that
was tested in animal models of arterial injury and vein
bypass grafting.35-37 A double-stranded oligodeoxynucle-
otide (14 base-pairs) was designed to incorporate the bind-
ing site for the transcription factor E2F, which controls the
expression of multiple genes that are responsible for cell
cycle progression. In a rabbit model, vein grafts treated
with the E2F decoy (edifoligide) in solution at the time of
implantation demonstrated a marked reduction in intimal
hyperplasia and resistance to graft atherosclerosis for up to
6 months. These exciting data, combined with the ease of
delivery (10-minute exposure of the vein to edifoligide in
solution) and presumed safety of this ex vivo approach, led
rapidly to a clinical development program.
The E2F decoy strategy for preventing vein graft failure
has now been examined in a series of clinical trials known as
the Project of Ex Vivo Vein Graft Engineering via Trans-
fection (PREVENT). PREVENT I was a single-institution
pilot study in 41 patients undergoing lower extremity vein
bypass.38 Intraoperatively, the veins were harvested,
mounted on a cannula, and inserted into a device for
pressure-mediated transfection with ODN (Fig 2). This
small study demonstrated safety and feasibility, and sug-
gested the possibility of biologic efficacy.
A corporate-sponsored (Corgentech, Inc, Palo Alto,
Calif) phase II trial (PREVENT II) in patients undergoing
Fig 2. Device used for intraoperative, pressure-mediated trans-
fection of vein grafts with ODN (edifoligide) in the PREVENT
clinical trials. Top panel, Assembled device with vial for adminis-
tering test article is shown. Bottom panel, Intraoperative photo-
graph demonstrates treatment of a vein graft before implantation
in PREVENT III.46coronary artery bypass graft surgery was completed in Ger-many.39 A total of 200 patients were randomized to treat-
ment with E2F decoy or saline control. Follow-up included
both clinical events and imaging (angiography and intra-
vascular ultrasound) at 1 year. As in the PREVENT-I trial,
no adverse events or complications were attributable to
decoy ODN treatment. The angiographic analysis revealed
a 30% relative reduction in critical stenosis (75%, P 
.03). Analysis of intravascular ultrasound images revealed a
statistically significant reduction in total wall volume (30%),
suggesting a positive influence on remodeling throughout
the lengths of the treated vessels. These studies led to
United States Food and Drug Administration approval of a
phase III trial for edifoligide.
Edifoligide was investigated in two parallel phase III
trials involving lower extremity (PREVENT III) and coro-
nary (PREVENT IV) bypass patients (cosponsored by Cor-
gentech and Bristol Myers Squibb). Both studies were
multicenter, randomized, double-blinded, and placebo-
controlled. In PREVENT III,40 1404 patients requiring
autogenous vein bypass for critical limb ischemia (CLI)
were randomized to either E2F decoy or saline delivered
with the aforementioned graft transfection apparatus. The
study involved vascular surgeons from 83 sites across North
America and was powered to detect a 30% reduction in the
primary end point of graft failure at 1 year.
The PREVENT III trial design41 was broadly inclusive
and therefore serves as an accurate representation of the
current population of CLI patients undergoing revascular-
ization procedures. Diabetes was present in 64% of the
patients, 48% had a history of advanced coronary artery
disease, 12% were on dialysis, and 28% had previously
undergone an infrainguinal bypass procedure. Tissue loss
was the presenting symptom in 75% of patients. High-risk
conduits were used in 24%, including alternative vein in
20% (15% spliced, 5% nongreat saphenous vein) and small
caliber (3 mm diameter) grafts in 6%. Most grafts (65%)
were placed to infrapopliteal targets.
Perioperative (30-day) mortality occurred in 2.7% of
patients in PREVENT III. Major morbidity included myo-
cardial infarction in 4.7% patients and early graft occlusion
in 4.3%. Ex vivo treatment with edifoligide was well toler-
ated. Unfortunately, there was no significant difference
between the treatment groups in the primary or secondary
trial end points, primary graft patency, or limb salvage. For
the overall cohort at 1 year, survival was 84%, primary
patency was 60%, primary-assisted patency was 77%, sec-
ondary patency was 79%, and limb salvage was 88%. Of
interest was that a significant improvement was observed in
secondary graft patency at 1 year (81% edifoligide, 76%
placebo, P  .0299).
The PREVENT IV investigators randomized 3014
patients at 107 sites.42 The primary end point was the
incidence of critical graft stenosis (75%) by coronary
angiography at 12 months, which was performed in 2400
patients (80%). Paralleling the results of PREVENT III,
these investigators found no difference in the occurrence of
the primary trial end point between treatment groups.
Other secondary end points, including the incidence of
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major adverse cardiac events, were also not different with
respect to edifoligide treatment.
The primary results of PREVENT III and IV demon-
strate conclusively that a single, ex vivo treatment of vein
grafts with edifoligide did not confer protection from graft
failure. Although none of the prespecified study end points
were met, a significant improvement in secondary patency
was observed in PREVENT III. The risk reduction ob-
served (4.7% absolute, 19.7% relative reduction in second-
ary patency events) was modest but not clinically irrelevant
and appears to suggest some beneficial biologic effect
that merits further inspection. Ongoing analyses from the
PREVENT III database, including subgroup event rates
and ultrasound findings, seek to better define the potential
source of this secondary patency benefit.
Ultimately the reasons underlying the failure of edifo-
ligide to meet the prespecified PREVENT trial end points
remain unknown. Lacking imaging tools to noninvasively
quantify IH within the grafts in these trials, it is unclear if
the treatment had its intended effect on wall thickness and
what role, if any, was played by remodeling.
Is SMC proliferation the correct target, and if so, was it
adequately suppressed by the study drug administered in
this fashion? Is the contribution of graft-extrinsic cells,
as suggested by recent small-animal studies,43 an
under-appreciated mechanism of graft IH? There are a
number of fundamental questions and plausible explana-
tions that cannot be addressed by the available data from
these trials, indicating a critical need for more mechanistic
clinical research on vein graft failure.
BEDSIDE TO BENCH: STUDYING VEIN GRAFT
ADAPTATION IN HUMANS
Vein graft failure is a complex clinical entity with com-
ponents derived from technical factors, patient-specific
variables, hemodynamic influences, and biologic responses
within the vein. Moreover, what accounts for the variability
in outcome for a good quality saphenous vein conduit
between two different patients and for the variability in
lesion formation along the course of a single conduit re-
mains largely unknown. Lessons from postangioplasty re-
stenosis in arteries have led to an appreciation of vascular
remodeling, in addition to IH, as a critical determinant of
vessel patency. Little is known about the spectrum of
remodeling of vein bypass grafts in humans, and the recent
results of the PREVENT trials demonstrate our limited
understanding of the process as well as the lack of adequate
imaging tools or surrogatemarkers tomonitor the effects of
a molecular intervention on the healing response. The
design of an effective intervention will depend on a more
complete understanding of the nature of normal vs patho-
logic vein graft remodeling in patients.
Recently, we have undertaken a prospective investiga-
tion exploring the relationship between systemic inflamma-
tion and vein graft remodeling in patients undergoing
lower extremity vein bypass. The goals of this project are:1. to determine if increased inflammation, as measured by
a panel of circulating markers, correlates with graft
failure and clinical events;
2. to quantify the structural and biomechanical changes in
arterialized veins using a combination of high resolution
ultrasound and magnetic resonance imaging;
3. to determine if there is a relationship between systemic
inflammation and unfavorable graft remodeling, and
4. to determine if a specific molecular signature can be
defined as a surrogate marker (or predictor) for vein
graft disease.
These ongoing studies have yielded some important
new insights. First, we have defined distinct temporal
phases of vein graft remodeling in the leg, with an early
(first month) period of outward remodeling, followed by a
more delayed process of increased wall stiffness during the
first 6 months (Fig 3).44 The early outward remodeling of
functioning vein bypass grafts is substantial (21% mean
increase in lumen diameter), correlates with initial shear
Fig 3. Changes in lumen diameter and wall thickness in lower
extremity vein grafts over time, assessed by ultrasound studies.44
A, Data demonstrate serial lumen diameter measurement of a
defined region (index segment) of vein grafts in 90 subjects.
B, Data show changes in wall stiffness assessed by graft pulse wave
velocity in 83 subjects. Results are presented as mean  standard
deviation.stress, and appears associated with subsequent clinical out-
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remodeling of the vein is a critical determinant and that its
mechanism requires further investigation. We hypothesize
that variability in endothelial function in the early postim-
plantation period is a primary factor in this response.
We have also demonstrated that systemic inflamma-
tion, as measured by high-sensitivity C-reactive protein
assay, correlates with clinical outcomes after lower extrem-
ity vein bypass (Fig 4).45 Patients with elevated high-
sensitivity C-reactive protein (5 mg/L) had a 2.3-fold
increased risk for adverse events after bypass surgery over a
mean follow-up of 342 days, most of which were vein
graft–related. This suggests that variability in the host
inflammatory milieu may correlate with healing responses
within the graft. Continuing studies seek to define a rela-
tionship between inflammatory markers and patterns of
graft remodeling over time.
CONCLUSIONS AND FUTURE DIRECTIONS
Armed with an expanding technology for implement-
ing specific genomic and proteomic interventions, the era
of in vivo tissue engineering has arrived. While the search
for suitable small arterial substitutes continues, it is clear
that an autogenous vein is the best substrate for designing
a durable arterial replacement. Although it is intuitive that
excessive SMC proliferation within the vein graft can lead
to an occlusive lesion, other factors such as remodeling,
endothelial function, and inflammatory cell recruitment
may also play a crucial role and would define a new set of
molecular targets and approaches. Translational research in
vein graft disease thus needs tomaintain focus in several key
areas:
1. continued investigations of the cellular and molecular
pathways of vein graft healing in suitable animal models;
2. better definition of patient-specific risk factors and ge-
netic determinants;
3. quantitative characterization of the spectrum of vein
graft remodeling in humans and the relationship be-
Fig 4. Relationship of preoperative high sensitivity C-reactive
protein (CRP) level to adverse events during follow-up in 91
patients undergoing lower extremity vein bypass surgery.45tween remodeling and clinical failure;4. development of imaging tools and circulating markers
to serve as surrogate end points in future clinical trials;
and
5. optimization of local approaches for the delivery of
potent biomolecules to the graft in a safe and efficient
fashion.
The PREVENT studies have demonstrated conclu-
sively that a molecular intervention can be applied to vein
grafts in an intraoperative setting, and appropriately tested
in well executed multi-center trials. Informed by the design
and outcome of these studies, future translational efforts
will have a greater likelihood to improve outcomes for
patients requiring vein bypass surgery.
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